What Retatrutide Trials Measure Beyond Weight Loss

Category: Metabolic & Body Composition

What Retatrutide Trials Measure Beyond Weight Loss

Posted on August 27, 2026

Introduction

If you are watching metabolic health change in midlife, the scale can feel both important and incomplete. Waist size shifts. Blood sugar creeps up. Strength feels harder to keep. A liver scan or blood panel may say something the bathroom scale never could. So when retatrutide trials report “metabolic improvement,” what did researchers actually measure besides weight?

The answer is useful, but not final. Retatrutide is an investigational triple receptor agonist studied in controlled human trials, not an approved consumer product. Current trials measured glucose control, body weight, fat mass, liver fat, waist, lipids, blood pressure, discontinuations, and adverse events. They do not yet tell us whether those changes translate into long-term outcomes such as fewer cardiovascular events, liver-related events, frailty outcomes, or diabetes complications.

Research Confidence

★★★★☆

Confidence is high that retatrutide trials measured metabolic endpoints beyond body weight, because multiple randomized human trials now report glucose, body-composition, liver-fat, lipid, and safety data. It is not five stars because retatrutide remains investigational, long-term outcomes are immature, liver-fat evidence comes from a small imaging substudy, and key trials were sponsor-funded.

Study Snapshot

• Study type: randomized, double-blind, placebo-controlled phase 3 trial
• Participants: 537 adults with type 2 diabetes inadequately controlled with diet and exercise alone
• Duration: 40 weeks plus 4-week safety follow-up
• Measured: HbA1c change at week 40, with body weight and cardiometabolic measures also reported
• Found: all retatrutide dose groups had greater HbA1c reductions than placebo, with greater decreases in body weight, triglycerides, non-HDL cholesterol, and systolic blood pressure
• Funding: Eli Lilly and Company

Why This Matters

Weight is a visible endpoint. Metabolic risk is often less visible.

That distinction matters in perimenopause, menopause, and ordinary aging because body composition can change even when weight does not move dramatically. Visceral fat can rise. Muscle can become harder to maintain. Glucose control can worsen. Liver fat risk can increase in people who would not think of themselves as having a liver problem.

Modern incretin trials, including retatrutide trials, are built around that broader picture. The better question is not only “how much weight changed?” It is “what kind of tissue changed, what happened to glucose and liver fat, and what did people stop taking because side effects became too much?” Those details make the results more honest.

HbA1c: The Glucose Endpoint Behind The Headline

HbA1c is a blood test that estimates average blood sugar over roughly two to three months. It is not a daily glucose diary. Think of it as a long-exposure photograph rather than a snapshot.

In the 2026 TRANSCEND-T2D-1 randomized, double-blind phase 3 trial, 537 adults with early type 2 diabetes received once-weekly subcutaneous retatrutide arms or placebo for 40 weeks. “Double-blind” means participants and trial staff did not know who was assigned to which arm during the trial. The primary endpoint, meaning the main result the trial was designed to test, was HbA1c change at week 40.

The trial reported greater HbA1c reductions with all retatrutide arms than placebo. It also reported greater decreases in body weight, triglycerides, non-HDL cholesterol, and systolic blood pressure. Those are different signals, not one interchangeable result. HbA1c speaks to glucose exposure. Triglycerides and non-HDL cholesterol speak to blood-fat patterns. Blood pressure is its own cardiovascular risk marker.

Earlier diabetes work pointed in the same direction. In a 2023 randomized phase 2 trial of 281 people with type 2 diabetes, retatrutide was compared with placebo and dulaglutide. At higher doses, the trial reported larger reductions in HbA1c and body weight than both comparators. Completion also matters: 84% completed the study, and 79% completed assigned study drug exposure.

Liver Fat And Body Composition Are Different Questions

Liver fat is not the same as waist size, and waist size is not the same as body composition.

The liver-fat substudy followed 98 participants from the phase 2 obesity trial who had metabolic dysfunction-associated steatotic liver disease, often shortened to MASLD. The trial used MRI-PDFF, an MRI method that estimates what fraction of the liver signal comes from fat. It is imaging, not a biopsy, so it does not directly show liver scarring or inflammation under a microscope.

In that randomized phase 2a substudy, liver fat at 24 weeks changed by minus 42.9%, minus 57.0%, minus 81.4%, and minus 82.4% across retatrutide arms, compared with plus 0.3% with placebo. Those are large imaging changes. They are also narrower than proof that liver disease outcomes improved, because the study was small and did not use biopsy-confirmed MASH resolution or fibrosis endpoints.

Body composition asks another question: when weight changes, what tissue accounts for it? In a 2025 randomized substudy of 189 people with type 2 diabetes, DXA scans were used to estimate fat mass and lean mass. DXA is an imaging scan better known from bone-density testing, but it can also estimate body compartments.

That substudy reported greater reductions in total fat mass with retatrutide 4 mg, 8 mg, and 12 mg arms than placebo over 36 weeks. The authors also reported that lean-mass loss as a share of total weight loss looked similar to other obesity medications. That still leaves a practical question for midlife and older adults: did strength, balance, or physical function change? This substudy was not built to settle that.

Waist, Lipids, Blood Pressure, And Safety Complete The Picture

Waist circumference matters because two people with the same body weight can carry fat differently. In metabolic research, waist is a simple proxy for central body size. It is less precise than imaging, but it is easy to repeat.

The phase 2 obesity trial enrolled 338 adults and followed participants for 48 weeks. Its primary and secondary endpoints centred on percentage body-weight change and weight-loss thresholds. At 48 weeks, mean body-weight change reached minus 24.2% in the 12 mg retatrutide group versus minus 2.1% with placebo. Cardiometabolic measures and safety were also tracked, which is why the trial matters beyond the headline number.

Safety endpoints are not a footnote. They tell you how often people had adverse events and how often those events led them to stop study drug exposure. In the obesity phase 2 trial, adverse-event discontinuation occurred in 6% to 16% of retatrutide groups. In TRANSCEND-T2D-1, discontinuation due to adverse events was 2% to 5% in retatrutide groups. Gastrointestinal events were the most common adverse events across major trials.

Those numbers do not answer whether any individual would tolerate the compound. They do show why discontinuation data belong beside metabolic endpoints, not after them.

What This Means For You

If you are reading retatrutide trials to understand metabolic health, do not stop at the weight graph. Look for the endpoint that matches the question you actually care about.

For glucose risk, HbA1c is central. For liver-fat risk, MRI-PDFF is informative but not the same as biopsy-confirmed liver outcome data. For body composition, DXA can separate fat mass from lean mass better than a scale, but it does not tell you whether someone became stronger. For tolerability, discontinuation percentages are often more practical than a long list of possible adverse events.

Retatrutide trial findings describe investigational study protocols. They are not dosing instructions, clinical advice, or evidence of an approved consumer product.

What This Tells Us About Women Specifically

Women were well represented numerically in several retatrutide trials: 55% of participants in TRANSCEND-T2D-1, 56% in the 2023 diabetes phase 2 trial, and 56% in the 2025 body-composition substudy. The obesity phase 2 trial reported a sex subgroup signal: women had larger mean weight reductions than men in the two highest-dose groups.

The missing details are just as important. Menopausal status was not reported. Hormone therapy use was not accounted for in a way that answers midlife questions. Results were not consistently broken out by sex for liver fat, fat mass, lean mass, adverse events, or function. For perimenopausal and postmenopausal readers, that is a real evidence gap.

Questions This Study Couldn't Answer

• Whether retatrutide reduces liver fat independently of weight loss, rather than mostly through weight loss.
• Whether MRI liver-fat reductions translate into biopsy-confirmed MASH resolution or fibrosis improvement.
• What happens after discontinuation or over multi-year follow-up.
• Whether older adults lose enough lean mass to affect strength, balance, or daily function.
• Whether women and men differ after adjusting for baseline body composition, menopause stage, hormone therapy use, and adverse-event patterns.
• How sponsor involvement may have shaped trial design, analysis, or reporting emphasis.

Future Research

The confidence rating would rise with large peer-reviewed phase 3 obesity and MASLD trials, longer follow-up, and liver studies using biopsy or clinical liver outcomes where appropriate. Prespecified sex and menopause analyses would also help. So would functional body-composition endpoints, such as strength, walking performance, and sarcopenia risk.

Sources

1. Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise: TRANSCEND-T2D-1. The Lancet. 2026. Human randomized double-blind placebo-controlled phase 3 trial, n=537. DOI: 10.1016/S0140-6736(26)00967-0

2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389:514-526. Human randomized double-blind placebo-controlled phase 2 trial, n=338 enrolled. DOI: 10.1056/NEJMoa2301972

3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. Human randomized double-blind placebo-controlled phase 2a substudy, n=98. DOI: 10.1038/s41591-024-03018-2

4. Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. 2023;402:529-544. Human randomized double-blind double-dummy placebo- and active-controlled phase 2 trial, n=281 randomized. DOI: 10.1016/S0140-6736(23)01053-X

5. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes. Lancet Diabetes & Endocrinology. 2025;13(8):674-684. Human randomized double-blind placebo-controlled phase 2 substudy, n=189. PubMed

6. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes. The Lancet. 2022;400:1869-1881. Human randomized double-blind placebo-controlled multiple-ascending-dose trial, n=72. DOI: 10.1016/S0140-6736(22)02033-5

Research Use And Availability

Retatrutide is supplied by Nuforme in Canada as a research-use-only peptide, with documentation and third-party testing standards. That status is separate from drug approval or clinical use. Readers comparing research categories may also see it discussed under Weight Management and Understanding research peptides. Health Canada has publicly identified unauthorized retatrutide-containing injectable peptide products, and FDA warning-letter material does not identify retatrutide as an approved active ingredient.

Final Thoughts

The most useful retatrutide trials are not only scale studies. They are metabolic endpoint studies, and each endpoint answers a different question. The current human evidence is substantial enough to take seriously, but not mature enough to answer the questions many midlife readers care about most: durability, function, liver outcomes, and sex-specific effects.